Clinical study on lamivudine combined with thymosin α1 in the treatment of chronic hepatitis B

Objective To evaluate the clinical efficacy of lamivudine comibined with thymosin α1. Method 98 chronic hepatits B patients were enrolled and randomized into the therapy group and the control group.49 cases in the therapy group received lamivudine and thymosin α1 for 26 weeks,then lamivudine simultaneously for 26 weeks;49 cases in the control group received lamivudine alone for 52 weeks.During the treatment blood routine examination?ALT?HBeAg?Anti-HBe?HBVDNA and HA were termly checked and measured. Results ALL 98 patients completed the study. The rates for ALT and HA to recover to normal and the rates for HBeAg and HBVDNA to change to be negative in combination group were superior to those in interferonα2b group.(81.6%vs53.1%,P0.005;44.9%vs22.4%,P0.025;42.9%vs20.4%,P0.025;79.6%vs51.0%,P0.005. Conclusion The efficacy of combination therapy appeared to be better than lamivudine group.